Ovarian Cancer Developments in 2017
Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, discusses recent exciting developments in the ovarian cancer field.
The year 2017 has been an important one for the ovarian cancer field. New drugs have been approved that give hope to people who have tried other therapies but whose cancer has come back.
Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, shares his thoughts on the exciting developments in his field. Three poly (ADP-ribose) polymerase (PARP) inhibitors were recently approved for people who have ovarian cancer which are administered orally, so they are convenient to take, and may be taken for a long time. He believes patients will benefit greatly from these drugs.
